Compare FRST & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | STRO |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | United States |
| Employees | N/A | 131 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.2M | 338.9M |
| IPO Year | 2006 | N/A |
| Metric | FRST | STRO |
|---|---|---|
| Price | $13.00 | $20.95 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 79.9K | ★ 126.0K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | ★ 477.27 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | $10.54 | N/A |
| P/E Ratio | $5.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.60 | $0.52 |
| 52 Week High | $14.55 | $27.96 |
| Indicator | FRST | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 48.20 | 51.59 |
| Support Level | $12.48 | $0.76 |
| Resistance Level | $14.42 | $27.96 |
| Average True Range (ATR) | 0.34 | 2.24 |
| MACD | 0.00 | -0.62 |
| Stochastic Oscillator | 55.86 | 22.48 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.